IRIS

PERSONENI, Nicola

PERSONENI, Nicola  

Dipartimento Scienze Biomediche  

Mostra records
Risultati 1 - 20 di 106 (tempo di esecuzione: 0.045 secondi).
Titolo Data di pubblicazione Autore(i) File
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 1-gen-2013 Rimassa, L; Pressiani, T; Boni, C; Carnaghi, C; Rota Caremoli, E; Fagiuoli, S; Foa, P; Salvagni, S; Cortesi, E; Tronconi, Mc; Personeni, N; Bozzarelli, S; Banzi, Mc; Fanello, S; Lutman, Fr; Giordano, L; Santoro, A
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 1-gen-2015 Santoro, A; Gebbia, V; Pressiani, T; Testa, A; Personeni, N; Bajardi, Ea; Foa, P; Buonadonna, A; Bencardino, K; Barone, C; Ferrari, D; Zaniboni, A; Tronconi, Mc; Carteni, G; Milella, M; Comandone, A; Ferrari, S; Rimassa, L
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 1-gen-2007 M, Colozza; E, Azambuja; Personeni, N.; F, Lebrun; Mj, Piccart; F., Cardoso
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 1-gen-2010 Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimassa, L; Personeni, N; Bozzarelli, S; Rossoni, G; Colombi, S; De Braud, Fg; Caligaris-Cappio, F; Lambiase, A; Bordignon, C
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 1-gen-2011 Personeni, N.; Torzilli, G.; Santoro, A.
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 1-gen-2018 Vigano, L; Pedicini, V; Comito, T; Carnaghi, C; Costa, G; Poretti, D; Franzese, C; Personeni, N; Del Fabbro, D; Rimassa, L; Scorsetti, M; Santoro, A; Solbiati, L; Torzilli, G
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 1-gen-2020 Campani, Claudia; Rimassa, Lorenza; Personeni, Nicola; Marra, Fabio
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 1-gen-2021 Jun, Tomi; Ozbek, Umut; Dharmapuri, Sirish; Hardy-Abeloos, Camille; Zhu, Huili; Lin, Jung-Yi; Personeni, Nicola; Pressiani, Tiziana; Nishida, Naoshi; Lee, Pei-Chang; Lee, Chieh-Ju; Hildebrand, Hannah; Nimkar, Neil; Paul, Sonal; Fessas, Petros; Naeem, Muntaha; Bettinger, Dominik; Khan, Uqba; Saeed, Anwaar; Huang, Yi-Hsiang; Kudo, Masatoshi; Rimassa, Lorenza; Marron, Thomas U; Pinato, David J; Ang, Celina
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 1-gen-2021 Personeni, Nicola; Rimassa, Lorenza
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 1-gen-2016 Mazzaferro, V. M.; Shaib, W.; Rimassa, L.; Harris, W.; Personeni, N.; El-rayes, B.; Tolcher, A.; Hall, T.; Wang, Y.; Schwartz, B.; Kazakin, J.; Michele, DROZ DIT BUSSET; Cotsoglou, C.; Papadopoulos, K.
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 1-gen-2022 Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 1-gen-2016 Personeni, N; Baretti, M; Bozzarelli, S; Spaggiari, P; Rubino, L; Tronconi, Mc; Fumagalli, U; Rosati, R; Giordano, L; Roncalli, M; Santoro, A; Rimassa, L
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 1-gen-2021 D'Alessio, Antonio; Cammarota, Antonella; Zanuso, Valentina; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 1-gen-2023 Dharmapuri, Sirish; Özbek, Umut; Jethra, Hiren; Jun, Tomi; Marron, Thomas U; Saeed, Anwaar; Huang, Yi-Hsiang; Muzaffar, Mahvish; Pinter, Matthias; Balcar, Lorenz; Fulgenzi, Claudia; Amara, Suneetha; Weinmann, Arndt; Personeni, Nicola; Scheiner, Bernhard; Pressiani, Tiziana; Navaid, Musharraf; Bengsch, Bertram; Paul, Sonal; Khan, Uqba; Bettinger, Dominik; Nishida, Naoshi; Mohamed, Yehia Ibrahim; Vogel, Arndt; Gampa, Anuhya; Korolewicz, James; Cammarota, Antonella; Kaseb, Ahmed; Galle, Peter R; Pillai, Anjana; Wang, Ying-Hong; Cortellini, Alessio; Kudo, Masatoshi; D'Alessio, Antonio; Rimassa, Lorenza; Pinato, David James; Ang, Celina
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 1-gen-2020 Personeni, Nicola; Lleo, Ana; Pressiani, Tiziana; Colapietro, Francesca; Openshaw, Mark Robert; Stavraka, Chara; Pouptsis, Athanasios; Pinato, David James; Rimassa, Lorenza
Biomarkers in Hepatocellular Carcinoma-Letter 1-gen-2012 Personeni, N; Rimassa, L; Santoro, A
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 1-gen-2019 Mennini, Fs; Marcellusi, A; Fabiano, G; Rimassa, L; Santoro, A; Personeni, N
Cabozantinib for the treatment of hepatocellular carcinoma 1-gen-2019 Personeni, N; Rimassa, L; Pressiani, T; Smiroldo, V; Santoro, A
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 1-gen-2019 Personeni, N.; Pressiani, T.; Rimassa, L.
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 1-gen-2022 Cammarota, Antonella; Zanuso, Valentina; D'Alessio, Antonio; Pressiani, Tiziana; Personeni, Nicola; Rimassa, Lorenza